Exploring Undiscovered Gems In Indian Stocks July 2024
In This Article:
The Indian stock market has experienced a notable fluctuation recently, declining by 2.0% over the last week, yet showing an impressive annual increase of 43%. In this context, identifying stocks with potential for robust earnings growth, forecasted at 16% annually, becomes particularly compelling for investors looking to uncover less recognized opportunities in such a dynamic market.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Voith Paper Fabrics India | NA | 10.79% | 9.57% | ★★★★★★ |
| NGL Fine-Chem | 12.35% | 15.70% | 9.76% | ★★★★★★ |
| Timex Group India | 2.24% | 16.39% | 61.31% | ★★★★★★ |
| Bengal & Assam | 4.48% | 3.82% | 47.41% | ★★★★★☆ |
| Indo Tech Transformers | 2.30% | 20.60% | 62.92% | ★★★★★☆ |
| Avantel | 10.67% | 34.84% | 36.61% | ★★★★★☆ |
| Spright Agro | 0.58% | 83.13% | 86.22% | ★★★★★☆ |
| KP Green Engineering | 13.73% | 47.60% | 61.28% | ★★★★★☆ |
| Apollo Micro Systems | 38.17% | 7.94% | 2.46% | ★★★★☆☆ |
| SG Mart | 16.73% | 99.32% | 94.08% | ★★★★☆☆ |
We're going to check out a few of the best picks from our screener tool.
Ethos
Simply Wall St Value Rating: ★★★★★★
Overview: Ethos Limited is a company that operates a chain of luxury watch boutiques across India, with a market capitalization of ?79.97 billion.
Operations: Ethos generates its revenue primarily through the trading of watches, accessories, and other luxury items. The company's gross profit margin as of the latest reported period stands at 30.09%, reflecting its cost management in relation to sales revenue.
Ethos, a lesser-known gem in India's retail sector, has showcased remarkable financial and operational growth. Over the past year, its earnings surged by 38.1%, outpacing the industry average of 28.7%. The company's debt-to-equity ratio dramatically improved from 59.1% to just 0.8% over five years, reflecting robust financial health and strategic debt management. Recently, Ethos reported a significant increase in annual revenue to INR 10,226 million and net income to INR 833 million for FY2024, underscoring its potential amidst competitive markets.
-
Get an in-depth perspective on Ethos' performance by reading our health report here.
-
Assess Ethos' past performance with our detailed historical performance reports.
Orchid Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Orchid Pharma Limited is a pharmaceutical company based in India that specializes in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals, with a market capitalization of ?69.48 billion.